Cytiva (Danaher)

What they make

7 inputs Cytiva (Danaher) supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Where they make it

7 facilities

Intelligence

What's known

Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.

• Concentration2020

  Danaher Corporation's 2020 acquisition of GE Healthcare Life Sciences for $21.4B — creating Cytiva — combined with its 2015 acquisition of Pall Corporation for $13.8B gave a single US industrial conglomerate control over three of the four most critical consumable inputs in biopharmaceutical manufacturing: (1) Pall: sterilizing-grade membrane filters used in every bioprocess step; (2) Cytiva: Protein A and other bioprocess chromatography resins used to purify monoclonal antibodies; and (3) Cytiva/HyClone: CHO cell culture media used to grow the cells that produce the antibodies. The fourth critical consumable — single-use bioreactor bags — is dominated by Sartorius. The biopharmaceutical industry's dependence on a single acquirer (Danaher) for three of its four critical consumables was largely invisible to policymakers at the time of acquisition. Danaher is a Rales brothers-controlled industrial conglomerate headquartered in Washington DC, not a life sciences company — meaning pharmaceutical supply chain policy implications were not analyzed in merger review.

  Danaher Corporation ↗

• Did you know2023

  Cytiva's MabSelect SuRe Protein A resin holds ~65% of the global market for the single most critical purification consumable in biopharmaceutical manufacturing — the Protein A capture column through which every commercial monoclonal antibody must pass. Humira (adalimumab), Keytruda (pembrolizumab), Dupixent (dupilumab), Herceptin (trastuzumab), and all other FDA/EMA-approved monoclonal antibodies are purified using Protein A chromatography as the primary capture step. The Protein A ligand binds to the Fc region of human IgG antibodies; the resin is loaded with bioreactor harvest, impurities are washed away, and purified antibody is eluted. A shortage or quality failure in Cytiva Protein A resin would simultaneously interrupt production of every monoclonal antibody drug globally within weeks — since biopharma manufacturers typically maintain only 1-3 months of resin inventory. Danaher's combined ownership of Cytiva (Protein A resins, bioreactors, cell culture media) AND Pall Corporation (sterile filters, tangential flow filtration) means that a single Washington DC industrial conglomerate controls critical consumables at nearly every step of a biopharmaceutical drug substance manufacturing process. No comparable concentration exists in any other critical supply chain.

  Cytiva ↗

• Origin2023

  Cytiva traces its heritage to Amersham Biosciences (Sweden) and Pharmacia Biotech — companies that pioneered agarose chromatography resins in the 1960s-1970s for protein purification. The first Sephadex gel filtration bead was developed at the Pharmacia Uppsala laboratory in 1959. When GE Healthcare acquired Amersham International (2004) and Amersham Biosciences for combined approximately GBP 9.7 billion, GE Healthcare Life Sciences became the dominant supplier of life science research and biopharma manufacturing tools. Danaher Corporation (Washington DC; known for its Danaher Business System lean manufacturing methodology) acquired GE Healthcare Life Sciences for USD 21.4 billion in 2020 — creating Cytiva as a standalone company within Danaher. Danaher's acquisition strategy (identify companies with recurring consumable revenues + dominant market positions) was perfectly executed: Cytiva's protein A resins, single-use bioreactor bags, and chromatography systems are consumables that biopharma manufacturers must continuously repurchase, creating the recurring revenue model Danaher prizes. The world's most critical biopharma manufacturing consumable company is controlled by a Washington DC conglomerate best known for lean manufacturing precision tools (Beckman Coulter, Fluke, Pall).

  Cytiva ↗

• Chokepoint2023

  Cytiva (a Danaher subsidiary) holds 35.7% of the global Protein A resin market — the single largest position in the most critical purification step for all 100+ FDA-approved monoclonal antibodies. Regulatory validation lock-in creates a functional near-monopoly: switching resins requires costly re-validation and an FDA filing that takes 12–18 months, so even when alternatives exist, they cannot be deployed quickly.

  Mordor Intelligence ↗